
|Articles|February 21, 2020
Signals Analytics Expands Rare Disease Data Coverage
Advertisement
Signals Analytics, analytics platform that leverages external data to uncover trends and predictive insights, announced the addition of 1,600 rare diseases, deepening its coverage of medical conditions and therapeutic areas.
The enhancement of rare diseases coverage offers pharmaceutical companies a comprehensive view of this hard-to-capture landscape with relevant insights that can allow opportunities for drug development, repurposing, and partnering.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
2
What Kinds of Disruption are GLP-1s Expected to Face
3
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
4
The Evolving Relationship Between FDA and Biotech
5




